Target for cancer therapy: proliferating cells or stem cells
- 15 December 2005
- journal article
- review article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 20 (3), 385-391
- https://doi.org/10.1038/sj.leu.2404075
Abstract
No abstract availableThis publication has 67 references indexed in Scilit:
- Dynamics of chronic myeloid leukaemiaNature, 2005
- ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid LeukemiaJournal of Clinical Oncology, 2005
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005
- The development of imatinib as a therapeutic agent for chronic myeloid leukemiaBlood, 2005
- Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatmentBlood, 2005
- Regulation of Hematopoietic Stem Cells by the NicheTrends in Cardiovascular Medicine, 2005
- Self-renewal and solid tumor stem cellsOncogene, 2004
- The biology of CML blast crisisBlood, 2004
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences of the United States of America, 2003
- Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.JCI Insight, 1994